Share on StockTwits

Repligen Corp. (NASDAQ:RGEN) VP Howard Benjamin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $20.34, for a total value of $813,600.00. Following the completion of the transaction, the vice president now directly owns 73,851 shares of the company’s stock, valued at approximately $1,502,129. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday, June 26th. They set a “buy” rating and a $26.00 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.

Shares of Repligen Corp. (NASDAQ:RGEN) traded down 5.56% on Thursday, hitting $19.18. The stock had a trading volume of 549,763 shares. Repligen Corp. has a 52 week low of $9.41 and a 52 week high of $24.68. The stock’s 50-day moving average is $22.44 and its 200-day moving average is $17.90. The company has a market cap of $612.5 million and a price-to-earnings ratio of 39.90. Repligen Corp. also saw some unusual options trading activity on Wednesday. Traders bought 611 put options on the company. This is an increase of approximately 536% compared to the typical daily volume of 96 put options.

Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Monday, August 11th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue for the quarter was down 10.9% on a year-over-year basis. Analysts expect that Repligen Corp. will post $0.29 EPS for the current fiscal year.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.